Finish enrollment in the sentinel cohort of the BEACON clinical trial
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 28 Feb 2023
- Due
- 31 Dec 2023
- Delivered
- by 7 May 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Finish enrollment in the sentinel cohort in 2023”
What we found
Evidence strength A What the grades mean
The company did not complete enrollment and dosing for the sentinel cohort in 2023, pushing the completion into the first half of 2024.
-
A Beam Therapeutics Inc. 8-K filed 2024-02-27
“Beam anticipates completing dosing in patients in the sentinel cohort and initiating dosing in patients in the expansion cohort in the first half of 2024.” ✓ confirmed on the page
-
A Beam Therapeutics Inc. 8-K filed 2024-05-07
“Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease” ✓ confirmed on the page
Market reaction: the shares moved +9.9% against the S&P 500 over the three sessions around the disclosure (26 Feb 2024 to 29 Feb 2024). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 28 Feb 2023
Deadline 31 Dec 2023 (“in 2023”)
-
Version 2 · stated 10 May 2023
Deadline 31 Dec 2023 (“2023”) · wording expected
“Beam expects to fully enroll the sentinel cohort in 2023.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Finish
- Deliverable
- Sentinel cohort enrollment
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-BEAM-003228 · Corrections policy